{"entity":{"id":"nct05093907","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of Capecitabine in colorectal cancer, run by BeyondBio Inc., now recruiting.","summary":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05093907 by BeyondBio Inc., with 27 participants planned, started 2021-08-31 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107, Capecitabine. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05093907","url":"https://clinicaltrials.gov/study/NCT05093907"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05093907","phase":"1/2","setting":"An Open-label, Single Center, Phase I/II Clinical Trial to Assess the Maximum Tolerated Dose, Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer Refractory or Intolerant to Standard of Care","sponsor":"BeyondBio Inc.","enrolled":27,"outcomes":[]},"route":"/trials/nct05093907/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}]}}